BRAFV600 mutant non-small-cell lung cancer resistant to Vemurafenib

Area of Science:

• Oncology
• Genomics
• Pharmacology

Background:

• Vemurafenib is a targeted therapy approved for BRAF V600-mutant melanoma.
• The efficacy of Vemurafenib in lung adenocarcinoma with BRAF mutations is not well-established.
• Tumor exome sequencing is increasingly used to identify actionable mutations.

Observation:

• A patient with lung adenocarcinoma harboring a rare activating BRAF mutation was treated with Vemurafenib.
• The patient had previously responded well to an alternative therapy.
• Switching to Vemurafenib resulted in disease progression.

Findings:

• The patient experienced tumor progression despite having an activating BRAF mutation.
• The off-label use of Vemurafenib did not provide clinical benefit.
• This led to a loss of disease-free survival and significant financial costs.

Implications:

• This case raises concerns about the clinical utility of next-generation sequencing for guiding off-label targeted therapy.
• It underscores the importance of strong clinical evidence before using agents in new indications.
• The financial toxicity of unsuccessful treatments is a critical consideration in patient care.